Compare Extra Space Storage, Inc. (EXR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Incyte Corporation — how do they compare? Extra Space Storage, Inc. trades at $148.88 (market cap $30.56B), while Incyte Corporation trades at $116.04 (market cap $22.99B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.48% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| EXR | INCY | |
|---|---|---|
Market Cap | $30.56B | $22.99B |
Sector | Real Estate | Health |
52-Week High | $152.75 | $118.52 |
52-Week Low | $126.67 | $67.38 |
Enterprise Value | $44.36B | $19.01B |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $148.89, up 2.33% over 24 hours, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.14 exceeding expectations. Revenue reached $3.38B in 2025, with a net income margin of 27.66%, though ROE remains modest at 6.92%. Recent news highlights steady expansion and a $550 million senior notes issuance, while analyst consensus is a $155.88 price target with a mix of Buy and Hold ratings.
Outlook is cautiously optimistic given consistent earnings performance and resilient demand, but risks include high debt levels, competitive pressures, and expense growth outpacing revenue. The stock's valuation metrics like P/E of 32.5 suggest it is priced for growth, yet investor sentiment is divided, with technical indicators showing neutral momentum near key support at $144.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
